Malik immediately began chemotherapy and was tested for genetic mutations. One month later, she celebrated her 40th birthday. Then she received a second opinion that would save her life.
Malik was found to have ROS1-positive cancer. According to the Lung Cancer Foundation of America, "ROS1-positive lung cancer occurs when a gene called ROS1 fuses with a nearby gene. This fusion causes the ROS1 gene to remain stuck in the 'on' position," which drives cancer growth.
Therefore Mass General Cancer Center was able to provide Ann with a targeted cancer therapy, a cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. The drug, oncologist Zosia Piotrowska, MD, MHS, tells "Chronicle," "was approved by the FDA but not for ROS1-positive cancers like hers. It was actually approved for a different type of lung cancer, [but] we were able to get it for her."
The results were stunning. Nine months after Malik's diagnosis, she had no signs of cancer. "As if the cancer had melted away," she says.
When Malik first met her doctors at Mass General, they said ROS1-positive cancer never really goes away. But they were hopeful that effective treatments available then and, in the future, would make it a manageable condition.
That expectation has proved to be true. For many years after her diagnosis, cancer returned to Malik's brain every six months or so. Each time, doctors successfully treated it with radiation therapy.
Fortunately, Malik has been clear of cancer since 2021. Today she is enjoying good health along with the company of Vinu and their now teenage children. She is also supporting other cancer survivors by teaching meditation, guiding them to find inner peace and resilience as she has.
"I would listen to other people's stories so I could form a belief that it was possible," she tells "Chronicle." "It's such a gift for me that I can be here and share my story so somebody out there knows that they can survive and they can thrive."